Immunotherapy with anti-programmed cell death 1 (anti-PD-1) therapy alone or in combination with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody ipilimumab is currently established as first line for patients with metastatic melanoma. This evidence concerns the gene PDCD1 and metastatic melanoma.